Neurocrine Biosciences (NBIX) EBITDA Margin Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.67 Bn | 34.93 Bn | 1.97 Bn | 1,673.00 |
| 2 | Zoetis | 30.59 Bn | 28.65 Bn | 1.62 Bn | -37.00 |
| 3 | RedHill Biopharma | 26.22 Bn | 26.22 Bn | - | - |
| 4 | United Therapeutics | 23.80 Bn | 21.65 Bn | 648.10 Mn | -1,442.00 |
| 5 | Curaleaf Holdings | 23.70 Bn | 23.70 Bn | 157.29 Mn | - |
| 6 | Viatris | 18.69 Bn | 16.89 Bn | 1.16 Bn | -1,299.00 |
| 7 | Neurocrine Biosciences | 16.86 Bn | 15.54 Bn | 800.70 Mn | 3,972.00 |
| 8 | Elanco Animal Health | 11.99 Bn | 11.57 Bn | 785.00 Mn | 5,310.00 |
| 9 | Dr Reddys Laboratories | 11.65 Bn | 11.51 Bn | - | - |
| 10 | Vireo Growth | 10.64 Bn | 10.52 Bn | 59.30 Mn | 674.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,972.00 |
| Dec 31, 2025 | -401.00 |
| Sep 30, 2025 | 925.00 |
| Jun 30, 2025 | 11,515.00 |
| Mar 31, 2025 | -9.00 |
| Dec 31, 2024 | 1,805.00 |
| Sep 30, 2024 | 1,529.00 |
| Jun 30, 2024 | -366.00 |
| Mar 31, 2024 | -552.00 |
| Dec 31, 2023 | -10,942.00 |
| Sep 30, 2023 | 3,936.00 |
| Jun 30, 2023 | -686.00 |
| Mar 31, 2023 | -3,158.00 |
| Dec 31, 2022 | 924.00 |
| Sep 30, 2022 | -748.00 |
| Jun 30, 2022 | -12,745.00 |
| Mar 31, 2022 | 7,457.00 |
| Dec 31, 2021 | -1,683.00 |
| Sep 30, 2021 | -2,645.00 |
| Jun 30, 2021 | 1,972.00 |